Cancer Biological Therapy Market - Global Forecast 2026-2032

The cancer biological therapy market is evolving rapidly with new scientific, operational, and regulatory complexities shaping the path ahead. For senior decision-makers, understanding the market’s latest shifts is critical to sustaining innovative advantage and driving tangible value across oncology care and product portfolios.

Market Snapshot: Cancer Biological Therapy Market

Registering strong expansion, the cancer biological therapy market is forecast to grow from USD 81.25 billion in 2025 to USD 91.17 billion in 2026, reaching USD 178.50 billion by 2032 at a CAGR of 11.89%. This trajectory signals increasing momentum for advanced biologically targeted therapies, supported by precision medicine approaches, data-integrated manufacturing, and dynamic collaboration models. Enhanced strategic investment, flexible commercial models, and proactive regulatory alignment are catalyzing accelerated adoption, while diverse stakeholders continue to adapt to shifting global frameworks and executional demands.

Scope & Segmentation

This executive report provides a detailed breakdown of the cancer biological therapy landscape, focusing on segments, global reach, and enabling technology developments shaping commercial opportunities and clinical impact.

Therapy Types: Cancer vaccines, CAR T-cell therapy, cytokine therapy, gene therapy, monoclonal antibodies (chimeric, human, humanized, murine), and oncolytic viral therapy each present distinct regulatory, clinical, and R&D considerations.
Clinical Applications: Indications span breast, colorectal, hematologic, melanoma, non-small cell lung, and prostate cancers, reflecting the nuanced clinical pathways, market access, and reimbursement structures involved in each area.
Administration Routes: Modalities include intramuscular, intravenous, oral, and subcutaneous delivery, each impacting patient adherence, treatment logistics, and provider workflows.
End Users: Utilization environments encompass ambulatory care centers, home healthcare, hospitals, research laboratories, and specialty clinics—each offering unique access challenges and growth opportunities.
Distribution Channels: Market reach is structured around direct sales, hospital pharmacies, online platforms, and retail pharmacies, supporting agile commercial strategies and heightened delivery efficiency.
Regions: Detailed analysis covers the Americas, Europe, Middle East & Africa, and Asia-Pacific, highlighting geographic differences in infrastructure, clinical adoption, and commercial models.
Technological Advances: Key trends include the adoption of digital infrastructure, the rise of modular manufacturing systems, and the integration of translational biomarker strategies to enable precision medicine.

Key Takeaways for Senior Decision-Makers

Leaders are advancing scientific differentiation with scalable and adaptable operational frameworks to secure sustainable market access within complex, evolving ecosystems.
Regulatory acceleration is matching the pace of clinical progress, with agencies favoring robust benefit-risk profiles and requiring evidence-based value demonstrations for reimbursement.
Payers are implementing outcomes-based reimbursement models and flexible contracting, driving pharmaceutical and biotech organizations to reframe value and risk-sharing strategies.
Optimizing supply chains and investing in regional manufacturing, including fill-finish capabilities, reduces exposure to policy uncertainty and variable import conditions.
Segment-specific strategies, aligning therapy type, indication, and administration route, enable focused launches, drive penetration in care settings, and foster effective patient engagement.
Market leaders address capabilities gaps in potency testing, long-term monitoring, and cold chain management through targeted partnerships and strategic investment, building operational resilience and compliance.

Impact of U.S. Tariff Adjustments on Supply Chains and Collaboration

Recent U.S. tariff changes have influenced sourcing, cross-border manufacturing, and global research collaboration in cancer biological therapies. Many organizations are restructuring supplier portfolios and boosting regional operations to improve resilience and safeguard clinical development timelines. Administrative challenges stemming from tariffs have led to the adoption of clarified cost structures and wider use of distributed clinical trial models, which help sustain multicenter research. These regulatory shifts have significant implications for operational choices, partnership strategies, and long-term alliance frameworks.

Methodology & Data Sources

This analysis synthesizes insights from peer-reviewed literature, regulatory guidance, technical white papers, and expert interviews. Cross-validation and scenario-based approaches were used to interpret policy changes, innovation drivers, and market constraints, addressing challenges from evolving regulations and incomplete proprietary data.

Why This Report Matters

Offers actionable insights that align research, manufacturing, and regulatory investments with anticipated market and policy developments.
Informs leaders on designing segmentation-driven launch strategies, enhancing supply chain resilience, and optimizing patient access in varied regional contexts.
Supports strategic decision-making with transparent methodologies and comprehensive market intelligence to sharpen competitive responses and policy adaptation.

Conclusion

Delivering value in the cancer biological therapy market now hinges on integrating scientific, operational, and market considerations. Adaptive strategies and coordinated partnerships will be essential to drive adoption, safeguard resilience, and support positive outcomes in a dynamic global environment.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biological Therapy Market, by Therapy Type

8.1. Cancer Vaccines
8.2. CAR T-Cell Therapy
8.3. Cytokine Therapy
8.4. Gene Therapy
8.5. Monoclonal Antibodies
8.5.1. Chimeric
8.5.2. Human
8.5.3. Humanized
8.5.4. Murine
8.6. Oncolytic Viral Therapy

9. Cancer Biological Therapy Market, by Administration Route

9.1. Intramuscular
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous

10. Cancer Biological Therapy Market, by Application

10.1. Breast Cancer
10.2. Colorectal Cancer
10.3. Hematologic Malignancies
10.4. Melanoma
10.5. Non-Small Cell Lung Cancer
10.6. Prostate Cancer

11. Cancer Biological Therapy Market, by End User

11.1. Ambulatory Care Centers
11.2. Home Healthcare
11.3. Hospitals
11.4. Research Laboratories
11.5. Specialty Clinics

12. Cancer Biological Therapy Market, by Distribution Channel

12.1. Direct Sales
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies

13. Cancer Biological Therapy Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Cancer Biological Therapy Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Cancer Biological Therapy Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Cancer Biological Therapy Market
17. China Cancer Biological Therapy Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc
18.6. Amgen Inc.
18.7. Astellas Pharma Inc.
18.8. AstraZeneca plc
18.9. Bausch Health Companies Inc.
18.10. Bayer AG
18.11. Biogen Inc.
18.12. bluebird bio, Inc.
18.13. Bristol-Myers Squibb Company
18.14. Eisai Co., Ltd.
18.15. Eli Lilly and Company
18.16. F. Hoffmann-La Roche Ltd
18.17. Gilead Sciences, Inc
18.18. GlaxoSmithKline PLC
18.19. Hikma Pharmaceuticals PLC
18.20. Incyte Corp
18.21. Johnson & Johnson
18.22. Johnson & Johnson Services, Inc,
18.23. Merck & Co. Inc
18.24. Novartis AG
18.25. Otsuka Pharmaceutical Co., Ltd
18.26. Pfizer Inc
18.27. Sanofi SA
18.28. Spectrum Pharmaceuticals, Inc.
18.29. Takeda Pharmaceutical Company Limited
18.30. Teva Pharmaceutical Industries Ltd

List of Figures

FIGURE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 126. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 127. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 128. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 129. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 140. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 141. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 142. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 143. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 155. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 156. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 157. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 158. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 162. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 163. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 164. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 165. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 176. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 177. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 178. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 179. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 183. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 184. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 185. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 186. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 190. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 191. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 192. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 193. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 204. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 205. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 206. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 207. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 208. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Cancer Biological Therapy market report include:

AbbVie Inc
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca plc
Bausch Health Companies Inc.
Bayer AG
Biogen Inc.
bluebird bio, Inc.
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc
GlaxoSmithKline PLC
Hikma Pharmaceuticals PLC
Incyte Corp
Johnson & Johnson
Johnson & Johnson Services, Inc,
Merck & Co. Inc
Novartis AG
Otsuka Pharmaceutical Co., Ltd
Pfizer Inc
Sanofi SA
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd

Table Information

Report Attribute	Details
No. of Pages	194
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 91.17 Billion
Forecasted Market Value ( USD ) by 2032	$ 178.5 Billion
Compound Annual Growth Rate	11.8%
Regions Covered	Global
No. of Companies Mentioned	27

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3504EUR$3,939USD£3,037GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3779EUR$4,249USD£3,276GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5123EUR$5,759USD£4,440GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6199EUR$6,969USD£5,372GBP

Market Snapshot: Cancer Biological Therapy Market

Scope & Segmentation

Key Takeaways for Senior Decision-Makers

Impact of U.S. Tariff Adjustments on Supply Chains and Collaboration

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Cancer Biological Therapy - Global Strategic Business Report

Immuno-Oncology Market - Global Forecast 2025-2032

Immunotherapy Drugs Market - Global Forecast 2025-2032

Cancer Immunotherapy Market Report 2025

Biological Therapies for Cancer: Technologies and Global Markets